Natixis Advisors LLC Buys 11,177 Shares of ICON Public Limited (NASDAQ:ICLR)

Natixis Advisors LLC raised its holdings in shares of ICON Public Limited (NASDAQ:ICLR - Free Report) by 6.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 177,761 shares of the medical research company's stock after purchasing an additional 11,177 shares during the period. Natixis Advisors LLC owned 0.22% of ICON Public worth $37,279,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Sierra Ocean LLC bought a new stake in shares of ICON Public in the 4th quarter valued at about $29,000. Park Place Capital Corp increased its stake in shares of ICON Public by 281.4% in the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company's stock valued at $47,000 after acquiring an additional 166 shares during the last quarter. Private Trust Co. NA increased its stake in shares of ICON Public by 48.8% in the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company's stock valued at $52,000 after acquiring an additional 82 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company's stock valued at $91,000 after acquiring an additional 169 shares during the last quarter. Finally, First Horizon Advisors Inc. increased its stake in shares of ICON Public by 33.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company's stock valued at $172,000 after acquiring an additional 151 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

ICON Public Stock Performance

ICON Public stock traded down $0.52 during mid-day trading on Thursday, hitting $183.96. 472,124 shares of the company's stock traded hands, compared to its average volume of 828,727. The firm has a 50 day simple moving average of $194.14 and a two-hundred day simple moving average of $228.16. ICON Public Limited has a fifty-two week low of $174.93 and a fifty-two week high of $347.72. The stock has a market cap of $14.86 billion, a price-to-earnings ratio of 19.30, a P/E/G ratio of 1.86 and a beta of 1.21. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34.

ICON Public (NASDAQ:ICLR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.01. The firm had revenue of $2.04 billion for the quarter, compared to analysts' expectations of $2.04 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. On average, research analysts expect that ICON Public Limited will post 13.38 EPS for the current fiscal year.

Analysts Set New Price Targets

ICLR has been the subject of a number of recent research reports. Barclays reduced their price target on ICON Public from $275.00 to $240.00 and set an "overweight" rating for the company in a research report on Friday, February 21st. Truist Financial reduced their price target on ICON Public from $284.00 to $262.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Citigroup reduced their price target on ICON Public from $300.00 to $290.00 and set a "buy" rating for the company in a research report on Monday, January 6th. Robert W. Baird reduced their price target on ICON Public from $221.00 to $203.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. cut their price objective on ICON Public from $280.00 to $265.00 and set an "overweight" rating for the company in a report on Monday, February 3rd. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $279.17.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.